期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

厌氧菌及抗厌氧菌抗菌药的研究进展 被引量：9

Research Progress on Anaerobes and Anti-anaerobes Antibiotics
下载PDF
导出
摘要 厌氧菌感染是目前比较常见的1种感染,由于厌氧菌会产生抗生素耐药性,所以一般抗生素治疗临床疗效不是很好。该文对厌氧菌进行分类并探讨每类菌株的耐药性机制的产生和对抗生素的敏感性,并试图找到解决厌氧菌感染的有效治疗方法。 Recently, anaerobes infection commonly occurs. The clinical efficacy of antibiotics is not good because of the resistance produced by anaerobes. The anaerobes were classified, the mechanism of resistance was investigated and the sensitivity of antibiotics was studied, trying to find out an efficient way to solve the problem of anaerobes infection in this paper.
作者 顾觉奋 黄文睿 刘亚光
机构地区 中国药科大学生命科学与技术学院
出处 《抗感染药学》 2008年第3期129-133,共5页 Anti-infection Pharmacy
关键词 厌氧菌 抗生素 耐药性机制 疗效 anaerobes antibiotics mechanism of resistance efficacy
分类号 R978.69 [医药卫生—药品]
  • 相关文献

参考文献22

  • 1[1]Ednie L,Shapiro S,Appelbaum PU.Antianaerobe activity of ceflobiprole,a new broad-spectrum cephalosporin[J].Diagn Microbiol Infec Dis,2007,58(1):133-136.
  • 2[2]Merriam CV,Citron DM,Tyrrell KL,et al.In vitro activity of azithromycin and nine comparator agents against 296 strains of oral anaerobes and 31 strains of Eikenella corrodens[J].Int J Antimicrob Agents,2006,28(3):244-248.
  • 3[3]Stein GE,Schooley S,Tyrreil KL,et al.Human serum activity of telithromycin,azithromycin and amoxicillin/clavulanate against aerobic and anaerobic respiratory pathogens[J].Int J Antimicrob Agents.2007,29(1):39-43.
  • 4[4]Snydman DR,Jacobus NV,McDermott LA,et al.National Survey on the Susceptibility of Bacteroides fragilis Group:Report and Analysis of Trends in the United States from 1997 to 2004[J].Antimicrob Agents Chemother.2007,51 (5):1649-1655.
  • 5[5]Koeth LM,Good CE,Appelbaum PC,et el.Surveillance of sus ceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents[J].J Antimicrob Chemother,2004,53(6):1039-1044.
  • 6[6]Aldridge KE,Ashcraft D,Cambre K,et el.Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group,Prevotella.Fusobacterium,Porphyromonas,and Peptostreptococcus species[J].Antimicrob Agents Chemother,2001,45(4):1238-1243.
  • 7[7]Pankuch GA,Appelbaum PC.Activities of Tizoxanide and Nitazoxanide compared to those of five other Thiazolides and three other agent against Anaerobic Species[J].Antimicrob Agents Chemother,2006,50(3):1112-1117.
  • 8[8]Finegold SM,Song Y,Liu C,at al.Clostridium clostridioforme:a mixture o f three clinically important species[J].Eur J Clin Microbiol Infect Dis,2005,24(5):319-324.
  • 9[9]Tanaka K,Mikamo H,Nakao K,et al.In vitro anacrobic activity of DX-619,a new Des-fluoro(6) quinolone[J].Antimicrob Agents Chemother,2 006,50(11):3908-3913.
  • 10[10]Odou MF,Muller C,Calvet L,et el.In vitro activity against anaerobes of retapamulin,a new topical antibiotic for treatment of skin infections[J].J Antimicrob Chemother,2007,59(4):646-651.

二级参考文献27

  • 1PANKEY GA.Tigecycine[J].J Antimicrob Chemother,2005,56(6):470-80.
  • 2ZHANEL GG,HOMENUIK K,NICHOL K,et al.The glycylcyclines:a comparative review with the tetracyclines[J].Drugs,2004,64(1):63-88.
  • 3FRITSCHE T,SADER H,JONES R.Activity of tigecycline tested against an international collection(1999-2003)of resistant bacterial pathogens[J].Clin Microbiol Infect,2005,11(4):382.
  • 4BRADFORD PA,WEAVER-SANDS DT,PETERSEN PJ,et al.In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-ahdominal infections[J].Clin Infect Dis,2005,41(Suppl 5):s315-S332.
  • 5BOUCHER HW,WENNERSTEN CB,ELIOPOULOS GM.In vitro activities of the glycylcycline GAR-936 against grampositive bacteria[J].Antimicrob Agents Chemother,2000,44(8):2225-2229.
  • 6BOUCHILLON SK,HOBAN DJ,JOHNSON BM,et al.In vitro evaluation of tigeeycline and comparative agents in 3049 clinical isolates 2001 to 2002[J].Diagn Microbiol Infect Dis,2005,51(4):291-295.
  • 7MILATOVIC D,SCHMITZ FJ,VERHOEF J,et al.Activities of the glycylcycline tigecycline(GAR-936) against 1924 recent European clinical bacterial isolates[J].Antimicrob Agents Chemother,2003,47(1):400-404.
  • 8EDLUND C,NORD CE.In-vitro susceptibility of anaerobic bacteria to GAR-936,a new glycylcycline[J].Clin Microbiol Infect,2000,6(3):158-163.
  • 9BETRIU C,CULEBRAS E,GOMEZ M,et al.In vitro activity of tigecycline against Bacteroides species[J].J Antimicrob Chemother,2005,56(2):349-352.
  • 10JACOBUS NV,MCDERMOTT LA,RUTHAZER R,et al.In vitro activities of tigecycline against the Bacteroides fragilis group[J].Antimicrob Agents Chemother,2004,48(3):1034-1036.

共引文献12

同被引文献81

引证文献9

二级引证文献52

抗感染药学
2008年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部